If you find yourself grappling with persistent fatigue, respiratory issues, or brain fog months after overcoming COVID-19, you are not alone.

After contracting  COVID-19, many individuals recover completely within a few days or weeks. However, for some, symptoms persist for extended periods, spanning weeks, months, or even years following the initial diagnosis. There are cases where individuals initially recover from COVID-19 only to experience a recurrence of symptoms or develop new ones within a few months. Surprisingly, even those who were asymptomatic during the initial infection may later manifest symptoms. Long-lasting symptoms can arise from both mild and severe cases of COVID-19.

No wonder Long COVID has been acknowledged as a concerning condition by WHO, NIH, and ICMR.

A global study discovered that in India alone, nearly 4 Crore people have experienced these long COVID symptoms since 2020, with the global figure exceeding 14 Crore. According to a study conducted by AIIMS, the prevalence of long COVID in India stands at a staggering 28.2% of those infected.

Dr. Giridhar Babu, a professor and head of lifecourse epidemiology at the Indian Institute of Public Health Bengaluru, emphasizes that COVID-19 should not be underestimated as a mere flu nor excessively feared. Instead, he urges the identification of the real concern posed by long COVID and its impact on various demographics, including young professionals, women, and even children.

A research paper from the Indian Council of Medical Research (ICMR) disclosed that 6.5% of patients hospitalized for moderate or severe COVID-19 died the following year. This marks the first time that the premier medical research agency in the country has quantified mortality among those unable to fully recover from COVID-19.

While the WHO estimates 10 to 20% of COVID patients develop prolonged symptoms, the ICMR study reports that over 17% of patients hospitalized after September 2020 experienced “post-COVID” conditions. These conditions encompassed fatigue, breathlessness, cognitive abnormalities, and brain fog.

The ICMR initiated its study prior to the WHO providing details on post-COVID complications, commonly referred to as “Long COVID.” This perplexing and challenging health condition, also known as post-acute sequelae of SARS-CoV-2 infection, affects individuals who have recovered from the acute phase of COVID-19. As researchers explore various approaches to manage lingering long COVID symptoms, one promising avenue involves the use of  Cordyceps militaris extract—a natural compound with a rich history in traditional medicine and a growing body of scientific evidence supporting its potential health benefits.

Long COVID is characterized by persistent symptoms extending beyond the typical recovery period from acute COVID-19 infection. Common symptoms include fatigue, shortness of breath, chest pain, brain fog, and joint pain, among others. The exact mechanisms behind long COVID are still under investigation, but it is believed to involve a complex interplay of immune dysregulation, inflammation, and other factors.

Cordyceps militaris extract – A Natural Solution

Cordyceps militaris is a fungus that has been used for centuries in traditional Chinese and Tibetan medicine. Traditionally, it was prized for its ability to enhance energy, improve respiratory function, and support overall vitality. Today, modern science is uncovering the bioactive compounds within Cordyceps militaris that may contribute to its health-promoting effects.

One key component of interest is adenosine, a nucleoside that plays a crucial role in various physiological processes, including energy metabolism. Adenosine may have bronchodilator effects which have been linked to improved oxygen utilization particularly relevant for individuals experiencing respiratory symptoms associated with long COVID. This means it could help open up the airways, making it easier to breathe, and may be beneficial for individuals with respiratory conditions.

Furthermore, Cordyceps militaris contains polysaccharides, peptides, and other bioactive compounds that have demonstrated anti-inflammatory and immunomodulatory properties. These properties could be beneficial in addressing the chronic inflammation and immune dysregulation observed in long COVID patients.

Several studies have explored the potential health benefits of Cordyceps militaris extract, and the existing findings are encouraging. Research has shown that Cordyceps militaris may have antioxidant and anti-inflammatory effects, which are crucial for combating the oxidative stress and inflammation associated with long COVID.

Additionally, studies suggest that Cordyceps militaris may enhance respiratory function and increase oxygen uptake, potentially alleviating symptoms such as shortness of breath in long COVID patients. The adaptogenic properties of Cordyceps militaris may also help the body better cope with stress, which is a common factor in the development and exacerbation of long COVID symptoms.

Long COVID poses significant challenges for individuals seeking to regain their health and well-being post-COVID-19 infection. As the medical community continues to explore effective treatment strategies, Cordyva containing Cordyceps militaris extract emerges as a natural compound with the potential to address certain aspects of long COVID, particularly those related to respiratory function, inflammation, and energy metabolism.

Cordyva, a novel product developed by Sinoveda in Canada, holds the promise of providing an effective solution to the challenges posed by long COVID. Formulated with an extract of cordyceps militaris, the product has demonstrated its efficacy in relieving long COVID symptoms within a remarkable 12-day period of consumption.

Having been introduced in Hong Kong and Korea, Cordyva has garnered enthusiastic reviews, with numerous individuals reporting relief from symptoms after just three days of use. The product is poised for launch in the United States and Canada in December 2023. In India, GCViDEAL has brought Cordyva to market and it is currently available for nutraceutical companies, paving the way for an imminent launch.